Hemab

Hemab Therapeutics

Despite tremendous innovation in hemophilia, treatment of rare bleeding and thrombotic disorders is still limited to blood transfusions and acute treatments.

Hemab leverages key insights into the treatment of bleeding and thrombosis to overcome longstanding hurdles in creating a preventative treatment for patients suffering from these disorders. Our lead asset, HMB-001, will initially target Glanzmann Thrombasthenia, enabling patients to proactively manage the disease for the first time. HMB-001 binds and recruits endogenous factor VIIa (FVIIa) to the site of vascular injury to overcome defects in patients’ ability to form healthy clots. Built on the heritage of recombinant FVIIa, our technology is prime for widespread indication expansion to other rare bleeding disorders